BioSpace News Archive

Combination patent to be granted in Europe until 2036

Symbility Solutions Inc. (“Symbility”) (TSXV: SY) announced that CoreLogic, Inc. (“CoreLogic”) (NYSE: CLGX), through its indirect wholly owned subsidiary, 2154638 Alberta Ltd., has completed the acquisition of all of the issued and outstanding common shares of Symbility not already owned by it or its affiliates for a purchase price of $0.615 per common share.

The device is indicated for unilateral thalamotomy with medication-refractory tremor patients

Floragraph Finishing Events Across the Nation Honor Donors

Fast-Growing Applied Health Signals Company Continues Moves to Bolster Management Team

CTI receives input on key elements of new Phase 3 trial design for patients with myelofibrosis and severe thrombocytopenia

Sanofi today announced that it will be transferring the listing of its American Depositary Shares (ADS) from the New York Stock Exchange (NYSE) to The Nasdaq Global Select Market (Nasdaq) effective December 31, 2018, after market close.

The Xiamen Encheng Group Co., Ltd., a pharmaceutical services and precision medicine-focused company located in Xiamen City, Fujian Province, China, announced today that it has entered into a strategic partnership with DarwinHealth, Inc, a New York City biotechnology company.

Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced that it will be participating in the J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco on Tuesday, January 8, 2019 at 10:00 a.m. Pacific Time.

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) introduces its financial outlook for 2019. Ligand expects revenue in 2019 to be at least $212 million, with up to an additional $40 million of potential milestone and license payments.